Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UL46
UPID:
PSME2_HUMAN
Alternative names:
11S regulator complex subunit beta; Activator of multicatalytic protease subunit 2; Proteasome activator 28 subunit beta
Alternative UPACC:
Q9UL46; Q15129
Background:
Proteasome activator complex subunit 2, also known as 11S regulator complex subunit beta, plays a crucial role in immunoproteasome assembly, vital for efficient antigen processing. This protein, identified by the accession number Q9UL46, is a part of the PA28 activator complex, significantly enhancing the generation of class I binding peptides by modifying the proteasome's cleavage pattern.
Therapeutic significance:
Understanding the role of Proteasome activator complex subunit 2 could open doors to potential therapeutic strategies.